Cord blood hope for elderly blood cancer patients
NCT ID NCT07441967
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a special chemotherapy combination followed by a single umbilical cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach is safe and reduces the risk of cancer returning within 180 days. Participants receive several drugs before the transplant to prepare their bodies, then are monitored for recovery and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
umbilical cord blood transplant plus chemotherapy (thiotepa, fludarabine, G-CSF, cytarabine, busulfan)
What this could lead to
If successful, this could offer a safer transplant option for elderly patients with blood cancers, potentially improving survival without relapse.
What could go wrong
This is a small, early-phase trial with only 44 participants. Risks include infection, graft-versus-host disease, and organ damage from the strong chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.